Idiopathic Membranous Nephropathy Clinical Trial
Official title:
Personalized Medicine for Membranous Nephropathy
Randomized, open label, multicentre (20 sites), prospective trial comparing the efficacy of
two therapeutic strategies to obtain clinical remission 1 year after diagnosis of Idiopathic
Membranous Nephropathy with nephrotic syndrome and anti-PLA2R1 (phospholipase A2 receptor 1)
antibodies:
- GEMRITUX protocol: 6 months of symptomatic antihypertensive and antiproteinuric therapy,
and if the nephrotic syndrome persists at month-6 (urinary protein/creatinine ratio
(UPCR) remains > 3.5 g/g and albuminemia < 30 g/l), two 375 mg/m2 rituximab infusions at
1-week interval.
- Personalized treatment:
- restricted anti-CysR activity at inclusion : 6-month symptomatic antihypertensive
and antiproteinuric treatment (KDIGO)
- restricted anti-CysR activity after 6 months of symptomatic treatment with
persisting nephrotic syndrome (UPCR remains > 3.5 g/g and albuminemia < 30 g/l):
two 375 mg/m2 rituximab infusions at 1-week interval;
- Anti-CTLD (C-type lectin domains ) 1/7 activity at inclusion or after 6 months with
persisting nephrotic syndrome (UPCR remains > 3.5 g/g and albuminemia < 30 g/l):
two 1g rituximab infusions at 2-week interval at month 0 and/or month 6.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06245707 -
the Effects of Different Treatment Schemes on Cognitive Function of Patients With Idiopathic Membranous Nephropathy
|
N/A | |
Recruiting |
NCT03864250 -
Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy
|
N/A | |
Completed |
NCT01845688 -
Clinical Study of QingReMoShen Granule to Treat Idiopathic Membranous Nephropathy
|
N/A | |
Completed |
NCT01180036 -
MEmbranous Nephropathy Trial Of Rituximab
|
Phase 2/Phase 3 | |
Withdrawn |
NCT01093781 -
Aliskiren in Patients With Idiopathic Membranous Nephropathy
|
N/A | |
Completed |
NCT00362531 -
Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome
|
Phase 2/Phase 3 | |
Recruiting |
NCT05839314 -
Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy
|
Phase 4 | |
Completed |
NCT00302523 -
Tacrolimus Treatment of Patients With Idiopathic Membranous Nephropathy
|
N/A | |
Terminated |
NCT03466801 -
The Efficacy of Prednisone and Combination Therapy With Methylprednisolone and Cyclophosphamide on IMN in Stage I.
|
N/A | |
Terminated |
NCT03475602 -
Membranous Nephropathy-associated Serological Antibody Predict the Prognosis of Idiopathic Membranous Nephropathy
|
||
Not yet recruiting |
NCT05850845 -
Study on the Application of Hyperspectral Imaging Technique in CTX Treatment of IMN
|
||
Not yet recruiting |
NCT05667896 -
Prognostic Model of GC/TAC in the Treatment of MN
|
||
Not yet recruiting |
NCT05667922 -
Prognostic Model of TAC in the Treatment of MN
|
||
Not yet recruiting |
NCT05667883 -
Prognostic Model of GC/CTX in the Treatment of MN
|
||
Not yet recruiting |
NCT05667909 -
Prognostic Model of Rituximab in the Treatment of MN
|
||
Recruiting |
NCT02173106 -
A Controlled Study of Steroids Plus Cyclosporin Therapy for Patients of Idiopathic Membranous Nephropathy
|
Phase 2 | |
Completed |
NCT01161459 -
Treatment of Idiopathic Membranous Nephropathy With Tripterygium Wilfordii Plus Steroid vs Tacrolimus Plus Steroid
|
N/A | |
Recruiting |
NCT03549663 -
Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy (IMN)
|
N/A | |
Not yet recruiting |
NCT05845762 -
Obinutuzumab in the Management of Idiopathic Membranous Nephropathy
|
||
Completed |
NCT00694863 -
Treatment With Synthetic ACTH in High Risk Patients With Membranous Nephropathy
|
Phase 2 |